-
1 week ago | 
urologytimes.com | Joshua J. Meeks |Benjamin P. Saylor
In a recent interview with Urology Times®, Joshua J. Meeks, MD, PhD, shared his thoughts on some of the notable ongoing trials in the non–muscle invasive bladder cancer (NMIBC) space and what urologists should be on the look-out for. “For a NMIBC, all you have to do is look forward to the metastatic setting.
-
2 weeks ago | 
urologytimes.com | Joshua J. Meeks |Benjamin P. Saylor
A report of disease-free survival analyses from the NIAGARA (6372115478112) trial of perioperative durvalumab (Imfinzi) plus neoadjuvant chemotherapy in muscle-invasive bladder cancer (MIBC) found that the treatment regimen was associated with a reduced risk of disease recurrence or death compared with neoadjuvant chemotherapy alone in patients in patients undergoing radical cystectomy.1The data were presented at the 2025 American Urological Association Annual Meeting in Las Vegas, by Joshua J.
-
4 weeks ago | 
urologytimes.com | Joshua J. Meeks |Benjamin P. Saylor
One of the top stories in urology in the first quarter of 2025 was the FDA’s approval of neoadjuvant durvalumab (Imfinzi) in combination with gemcitabine and cisplatin, followed by adjuvant durvalumab monotherapy following radical cystectomy, for adult patients with muscle invasive bladder cancer (MIBC).1 In a recent video interview with Urology Times®, Joshua J.
-
Oct 14, 2024 | 
mibluedaily.com | Joshua J. Meeks
Each day, approximately in the United States turn 65, making them eligible for health insurance coverage through the federally managed Medicare program. Additionally, some individuals younger than 65 may be eligible for Medicare, including those with a long-term disability or certain diseases. There are many Medicare coverage options individuals should understand before picking the right plan for them. There are two main distinctions between Medicare plans: Original Medicare and Medicare Advantage.
-
Sep 30, 2024 | 02605-8/abstract?rss=yes&sz=64)
europeanurology.com | Roger Li |Joshua A. Linscott |James Catto |Joshua J. Meeks |Siamak Daneshmand |Bishoy M Faltas | +4 more
Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes aDepartment of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USAbDepartment of Immunology, H.
-
Jul 2, 2024 | 
nature.com | Roger Li |Joshua J. Meeks |Ashish M. Kamat
Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-03025-3, published online 6 June 2024In the version of the article initially published, in the key to Fig. 2b, the red diamond representing “Recurrence/NR” has been corrected to a green diamond to match the graph. This correction has been made to the HTML and PDF versions of the article. About this articleLi, R., Shah, P.H., Stewart, T.F. et al.
-
Jun 18, 2024 | 
nature.com | Roger Li |Joshua J. Meeks |Ashish M. Kamat
Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-03025-3, published online 6 June 2024In the version of the article initially published, the text “Immune-related adverse effects were exclusively associated with pembrolizumab” and, in the following sentence, also referring to adverse effects, “…all related to pembrolizumab” has been removed from the Abstract.
-
Jun 6, 2024 | 
nature.com | Roger Li |Joshua J. Meeks |Ashish M. Kamat
AbstractCretostimogene grenadenorepvec is a serotype-5 oncolytic adenovirus designed to selectively replicate in cancer cells with retinoblastoma pathway alterations, previously tested as monotherapy in bacillus Calmette–Guérin (BCG)-experienced non-muscle-invasive bladder cancer.
-
May 4, 2024 | 
onclive.com | Joshua J. Meeks
Joshua J. Meeks, MD, PhD, the Edward M. Schaeffer, MD, PhD, Professor of Urology and an associate professor of Urology and Biochemistry and Molecular Genetics at Northwestern University Feinberg School of Medicine, discusses key takeaways from a session that he participated in during the 2024 American Urological Association Annual Meeting regarding effectively implementing recent therapeutic advances across the disease continuum of bladder cancer.
-
Feb 28, 2024 | 
urotoday.com | Joshua J. Meeks
Zach Klaassen and Joshua Meeks discuss the ongoing BCG shortage impacting bladder cancer treatment, tracing its origins back to production issues in 2012 and guideline changes in 2016 that increased BCG demand. They highlight the shift towards using Gemcitabine-Docetaxel (Gem/Doce) as both a salvage and primary treatment for high-risk bladder cancer due to its effectiveness and availability.
